| 23.08 09:08 | dpa-AFX: ALXN & Takeover Rumors, AMGN's JASMINE Blooms, CLSD Sees The Writing On The Wall |
| 26.07 14:47 | dpa-AFX: Alexion Gets Positive Opinion From CHMP For SOLIRIS For Treatment Of NMOSD |
| 26.07 14:10 | dpa-AFX: *ALEXION GETS POSITIVE CHMP OPINION FOR SOLIRIS FOR TREATMENT OF NMOSD |
| 24.07 13:13 | dpa-AFX: Alexion Boosts FY19 Outlook |
| 24.07 12:34 | dpa-AFX: *ALEXION Q2 GAAP EPS $2.04; NON-GAAP EPS $2.64 |
| 20.06 14:20 | dpa-AFX: *ALEXION PHARMA: FDA ACCEPTS SBLA FOR ULTOMIRIS UNDER PRIORITY REVIEW FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME |
| 14.06 12:35 | dpa-AFX: *ALEXION PHARMA SAYS POSITIVE PHASE 3 EXTENSION DATA FOR ULTOMIRIS PRESENTED AT EHA CONGRESS |
| 25.05 05:18 | dpa-AFX: Biotech Stocks Facing FDA Decision In June 2019 |
| 25.05 05:18 | dpa-AFX: Biotech Stocks Facing FDA Decision In June 2019 |
| 25.05 05:17 | dpa-AFX: Biotech Stocks Facing FDA Decision In June 2019 |
| 25.05 05:17 | dpa-AFX: Biotech Stocks Facing FDA Decision In June 2019 |
| 25.04 12:53 | dpa-AFX: Alexion Pharmaceuticals Inc. Q1 adjusted earnings Beat Estimates |
| 25.04 12:53 | dpa-AFX: Alexion Pharmaceuticals Inc. Q1 adjusted earnings Beat Estimates |
| 25.04 12:42 | dpa-AFX: *ALEXION Q1 NON-GAAP EPS $2.39, 42% INCREASE FROM PRIOR YEAR |
| 25.04 12:42 | dpa-AFX: *ALEXION Q1 TOTAL REVENUES $1.14 BLN, UP 23% FROM PRIOR YEAR |
| 25.04 12:35 | dpa-AFX: *ALEXION Q1 GAAP EPS $2.61, UP 135% FROM LAST YEAR |
| 20.03 12:07 | dpa-AFX: *ALEXION AND ZEALAND PHARMA ANNOUNCE COLLABORATION TO DEVELOP PEPTIDE THERAPIES FOR COMPLEMENT-MEDIATED DISEASES |
| 20.03 11:37 | dpa-AFX: *ALEXION TO PROVIDE AFFIBODY WITH UPFRONT PAYMENT OF $25 MLN, WITH POTENTIAL FOR MILESTONES OF UP TO $625 MLN |
| 20.03 11:36 | dpa-AFX: *ALEXION AND AFFIBODY AB ANNOUNCE PARTNERSHIP TO CO-DEVELOP ABY-039 |
| 04.02 13:01 | dpa-AFX: Alexion Pharmaceuticals Q4 18 Earnings Conference Call At 8:00 AM ET |
|
|
